We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

MorphoSys's Partner Heptares Initiates Proprietary Therapeutic Antibody Program

News   Aug 06, 2015

 
MorphoSys's Partner Heptares Initiates Proprietary Therapeutic Antibody Program
 
 
Advertisement
 

RELATED ARTICLES

Discovering the Strategies Tumor Cells Use To Evade Immune Attack

News

A new study has uncovered the strategies tumor cells use to evade immune system attack. The method developed for this work contributes to a better understanding of the "arms race" between immune defense and disease.

READ MORE

NIH Announces Clinical Trial To Test Monoclonal Antibodies for COVID-19

News

A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease.

READ MORE

Circulating DNA From Tumor Could Predict Immunotherapy Outcome

News

A newly developed test that detects changing levels of tumor fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from immunotherapy, according to researchers.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE